Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

Rarely do any stocks hold up during a recession, and those that do aren’t guaranteed to do so in the next one. Recessions ...

Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

Shares with over 50 years of consecutive dividend increases rarely go under the radar. But that might be what’s happening ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds. Based on the trading activity, it appears that the significant investors are ...